Skip to Content
U.S. National Institutes of Health
Last Updated: 06/25/14

Molecular Radiation Therapeutics Branch (MRTB)

The MRTB is a RRP in-house program that serves as a focal point for collaborations with: the Developmental Therapeutics Program (DTP) and Cancer Therapy Evaluation Program (CTEP) in DCTD, investigators in the Radiation Biology and Radiation Oncology Branches in the Center for Cancer Research (CCR), and university and industry collaborators specifically addressing research and development needs in combined modality therapy using radiation.  The MRTB participates as a major role in developing radiosensitizers as part of the recently initiated NCI Experimental Therapeutics Program (NExT).

The primary mission of the MRTB is to facilitate the generation of preclinical data that will support clinical trials with radiation modifiers. The program that was first initiated was called the Radiation Modifiers Evaluation Module (RAMEM) which was a unique national and international resource to assist a wide range of potential collaborators in providing preclinical data to support the safe conduct of drug approval for clinical trials involving radiation modifiers. Adopting such concepts, currently MRTB plays a central role developing the overall design for clinical implementation of radiation modifiers coupled with updates on advances in approaches, particularly, in molecular targeted therapy.

Through these efforts, the MRTB stimulates discussion among various disease-site / biology working groups that interact periodically to bring in new agents as radiation modifiers from either the CTEP portfolio or company interactions.

Working groups include:

  1. Brain Metastasis in Breast Cancer
  2. Colorectal Cancer
  3. Sarcoma
  4. Lung Cancer
  5. Radiation and Immune Modulation
  6. Head and Neck Cancer

Contact Information:

Mansoor Ahmed, PhD
Acting Chief
240-276-5700
mansoor.ahmed@nih.gov